A detailed history of Engineers Gate Manager LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 57,768 shares of ARWR stock, worth $1.13 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
57,768
Holding current value
$1.13 Million
% of portfolio
0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.36 - $29.54 $1.12 Million - $1.71 Million
57,768 New
57,768 $1.12 Million
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $29,553 - $40,698
-1,128 Reduced 5.26%
20,312 $545,000
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $984,108 - $1.62 Million
-39,114 Reduced 64.59%
21,440 $764,000
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $1.43 Million - $2.33 Million
60,554 New
60,554 $1.54 Million
Q2 2022

Aug 15, 2022

SELL
$27.79 - $50.61 $640,003 - $1.17 Million
-23,030 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $704,047 - $1.24 Million
17,770 Added 337.83%
23,030 $1.06 Million
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $208,426 - $296,045
-3,588 Reduced 40.55%
5,260 $349,000
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $243,911 - $354,962
4,178 Added 89.46%
8,848 $552,000
Q2 2021

Aug 16, 2021

BUY
$62.15 - $90.32 $290,240 - $421,794
4,670 New
4,670 $387,000
Q1 2020

May 15, 2020

SELL
$20.56 - $63.12 $717,030 - $2.2 Million
-34,875 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$28.14 - $73.01 $508,546 - $1.32 Million
18,072 Added 107.55%
34,875 $2.21 Million
Q3 2019

Nov 14, 2019

SELL
$26.26 - $34.86 $1.26 Million - $1.67 Million
-47,928 Reduced 74.04%
16,803 $474,000
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $856,405 - $1.42 Million
49,134 Added 315.02%
64,731 $1.72 Million
Q1 2019

May 15, 2019

BUY
$12.05 - $20.18 $187,943 - $314,747
15,597 New
15,597 $286,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.